Recent advances in research on vine tea, a potential and functional herbal tea with dihydromyricetin and myricetin as major bioactive compounds

Qili Zhang a,*, Yanfang Zhao a, Meiyan Zhang b, Yalu Zhang c, Hongfang Ji a, Liang Shen a

a College of Life Sciences, Shandong University of Technology, Zibo, Shandong 255000, China
b Department of Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China
c Department of Pharmacy, The Affiliated Hospital of Jining Medical College, Jining, Shandong 272100, China

A R T I C L E   I N F O

Article history:
Received 25 February 2020
Received in revised form 7 October 2020
Accepted 12 October 2020
Available online 14 October 2020

Keywords:
Vine tea
Flavonoids
Dihydromyricetin
Myricetin
Pharmacological effects
Molecular mechanism

A B S T R A C T

Vine tea has been used as an herbal tea by several ethnic minorities for hundreds of years in China. Flavonoids, a kind of indispensable component in a variety of nutraceutical, pharmaceutical and cosmetic applications, are identified to be the major metabolites and bioactive ingredients in vine tea. Interestingly, vine tea exhibits a wide range of significant bioactivities including anti-oxidant, anti-inflammatory, anti-tumor, antidiabetic, neuroprotective and other activities, but no toxicity. These bioactivities, to some extent, enrich the understanding about the role of vine tea in disease prevention and therapy. The health benefits of vine tea, particularly dihydromyricetin and myricetin, are widely investigated. However, there is currently no comprehensive review available on vine tea. Therefore, this report summarizes the most recent studies investigating bioactive constituents, pharmacological effects and possible mechanisms of vine tea, which will provide a better understanding about the health benefits and preclinical assessment of novel application of vine tea.

© 2020 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Tea culture has been carried forward in China for thousands of years. Teas are broadly divided into green tea, oolong tea and black tea, i.e., non-fermented, semi-fermented and fermented as a result of their diverse manufacturing processes [1]. Since ancient times, many herbs have always been used to prepare tea-like beverages locally capable of improving health or inhibiting all kinds of diseases in various regions of China on the basis of Camellia sinensis [2,3]. These herbs, so-called non-Camellia tea varieties, such as vine tea and bitter tea, form a sub-culture in the Chinese tea culture [4].

The tender stems and leaves of Ampelopsis grossedentata, named vine tea or Mao Yan Mei, have traditionally been used as a health tea and folk herbal medicine by TuJia, Yao and other ethnic minorities in China [5]. According to the records in the Chinese Materia, vine tea exhibits a wide variety of beneficial properties, such as clearing away heat, detoxification, diuresis, activating blood circulation and dissipation of blood stasis. In addition, it was traditionally used as a folk medicine by most local people to treat pyretic fever and cough, stab wounds, bruises, jaundice hepatitis and pain in pharynx and larynx [6]. A study reported that high levels of flavonoids [7], especially dihydromyricetin (DMY, also known as ampelopsin), myricetin and myricitrin [8], are present in vine tea. It is well known that flavonoids possess many special functions and are one of the most potent nutraceuticals in food and pharmaceutical products [9].

Modern investigations indicate that vine tea exhibits a number of beneficial pharmacological properties (Fig. 1), such as hypoglycemic [10,11], antioxidant [5,12,13], anti-thrombosis function [14], anti-tumor [15,16], anti-inflammatory [10,17] and antibacterial activities [18], but no toxicity [19]. In addition, the main pharmacological effects of vine tea are similar to those of Camellia sinensis, i.e., anti-inflammatory, antioxidant, anticancer, anti-obesity, cardioprotective activity and other activities [20–22]. With the Chinese and English words of “vine tea”, “Ampelopsis grossedentata”, “dihydromyricetin”, “myricetin”, “flavonoids”, “extraction”, “separation”, “purification” and “pharmacological activity” as keywords, we combined and searched the relevant literatures published in PubMed, Web of Science, ScienceDirect, China
2.2. Polysaccharides

Bioactive materials, such as ginkgo polysaccharide, have anti-virus, tumor and other biological effects [43,44]. In studies by Ma et al. [26] and Gao et al. [33], the ethyl acetate and n-butanol fraction of vine tea extract showed high 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) scavenging activities in comparison to the ascorbic acid (VC) group. The polysaccharides (ALPS and ASPS) showed effective DPPH scavenging ability. Moreover, according to in vitro evaluation, ASPS has a stronger antioxidant activity potential than ALPS [45].

Qin et al. [47] reported that DMY shows effective DPPH (+), 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt radical cation (ABTS (+)) and O2 (-) scavenging activities. In addition, DMY has the ability to increase the activity of total superoxide dismutase and to decrease the level of lipid peroxidation. Moreover, DMY can also decrease the levels of malondialdehyde in LPS-treated piglets. The studies revealed that DMY has the ability to decrease lipopolysaccharide (LPS)-induced oxidative stress, which may be attributed to its reactive oxygen species scavenging activities.

Myricetin can scavenge many radicals and ions. Examples of such radicals include ABTS (+) and DPPH (+) [48]. However, it cannot scavenge reactive oxygen species (ROS) in medinadene-stressed modeling [49]. Moreover, myricetin protects cells against H2O2-induced cell damage via inhibition of ROS generation and activation of antioxidant enzymes [50]. A study by Qin et al. [51] reported that the antioxidant effect of myricetin on hepatic human hepatocellular carcinomas (HepG2) cells is related to the activation of the nuclear factor E2-related factor 2 (Nrf2)-induced antioxidant reaction element. Altogether, vine tea might be developed as a novel antioxidant agent.

2.3. Organic acids, steroids and others

Studies have determined that vine tea and its main flavonoids are potent anti-inflammatory agents. Signaling pathways involved in anti-inflammatory mechanisms of vine tea are shown in Fig. 3. A study reported that Ampelopsis grossedentata can alleviate ulcerative colitis via the interleukin-1 receptor-associated kinase 1/TNF receptor associated factor 6/nuclear factor-κB (IRAK1/TRAF6/NF-κB) signaling pathways [52].

Hou et al. [53] demonstrated that DMY downregulates the levels of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in LPS-induced mouse mononuclear macrophage leukemic cells (RAW 264.7) macrophages. Similar results showed that DMY increases the content of interleukin-10 (IL-10) in LPS-induced mice. In addition, it also attenuates the protein expression of inducible nitric oxide synthase (iNOS), TNF-α, and cyclooxygenase-2 (COX-2) in macrophages. Moreover, DMY inhibits the activation of NF-κB, NF-κB alpha (κBα), p38 mitogen-activated protein kinase (p38) and c-Jun NH2-terminal kinase (JNK) signaling pathways. The occurrence of Alzheimer disease (AD) and Parkinson’s disease (PD) may be...
attributed to the microglia-induced neuroinflammation. The mechanism experiment indicated that the NF-κB and Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathways play the main role in the suppression of neuro-inflammation of DMY [54]. DMY could alleviate inflammation in collagen induced arthritis (CIA) rats and attenuate IL-1β-induced activities in fibroblast-like synoviocytes through suppression of NF-κB signaling [55].

Several researches have demonstrated that myricetin has anti-inflammatory activity [50]. Myricetin may be an effective agent for the therapy of periodontitis by inhibiting the production of IL-6, interleukin-8 (IL-8) and matrix metalloproteinase-3 (MMP-3) [56]. Moreover, myricetin alleviates periodontitis by activating extracellular signal-regulated kinases-1/2 (ERK-1/2), Akt and p38, inhibiting COX-2 activation in human gingival fibroblasts, as well as inhibiting the degradation of IκB and the synthesis and expression of prostaglandin E2 (PGE2) [57]. Similar results showed that myricetin can decrease the levels of NO and PGE2 as well as the expression of iNOS and COX-2 in RAW 264.7 macrophages [58]. In addition, myricetin suppresses the expression of phorbol ester-induced COX-2 via NF-κB signaling pathway [59]. Moreover, myricetin has anti-rheumatoid arthritis activity via JNK and p38 mitogen-activated protein kinase (MAPK) signaling pathways in human synovial sarcoma (SW982) cells [60]. The results indicated that myricetin possesses activity against acute colitis by inhibiting the over-expression of inflammatory cytokines via phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway in mice [61]. These results revealed that vine tea has a great potential to be an anti-inflammatory drug.

3.3. Antidiabetic activity

Several researches have revealed that vine tea may have the

| No. | Compound name                        | Sub-class | Refs.                  |
|-----|--------------------------------------|-----------|------------------------|
| 1   | Quercetin-3-O-β-D-glucoside          | Flavonol  | [25]                   |
| 2   | Apigenin                             | Flavone   | [25]                   |
| 3   | Dihydromyricetin                     | Flavanol  | [6,25–33]              |
| 4   | Dihydroquercetin                     | Flavanon  | [25–27,31]            |
| 5   | Myricetin-3-O-β-D-glucoside          | Flavonol  | [29,33]                |
| 6   | 3-dihydroxyquercetin                 | Flavonol  | [33]                   |
| 7   | Quercetin-3-0-β-D-xylloside          | Flavonol  | [33]                   |
| 8   | Kaempferol-3-0-α-L-rhamnoside        | Flavonol  | [33]                   |
| 9   | Phloretin                            | Chalcone  | [33]                   |
| 10  | Phlorizin                            | Chalcone  | [33]                   |
| 11  | Quercetin-3-0-α-L-rhamnoside         | Flavonol  | [26,27,33,34]          |
| 12  | Quercetin                            | Flavonol  | [25,34]                |
| 13  | Quercetin-3-galactoside              | Flavonol  | [34]                   |
| 14  | Luteolin                             | Flavone   | [34]                   |
| 15  | Vitexin                              | Flavanone | [34]                   |
| 16  | Vitexin-2’-O-rhamnoside              | Flavanone | [34]                   |
| 17  | Isodihydromyricetin                  | Flavonol  | [26,33,35]             |
| 18  | Myricetin                            | Flavonol  | [25,26,28–30,32,33,35,36] |
| 19  | Myricetin-3-0-α-L-rhamnoside         | Flavonol  | [26–30,32,33,37]       |
| 20  | Myricetin-3-0-β-D-galactopyranoside  | Flavonol  | [37]                   |
| 21  | Apigenin                             | Flavone   | [34,38]                |
| 22  | Hesperidin                           | Flavonol  | [33,38,39]            |
| 23  | Kaempferol                           | Flavonol  | [33,34,38]            |
| 24  | Rutin                                | Flavonol  | [34,39]                |
| 25  | 6,7-dihydroxy-3’-methoxy-4’, 5’-methylenedioxy isoflavone | Isoflavone | [40] |
| 26  | 6,7-dihydroxy-3’-methoxy-4’, 5’-methylenedioxy isoflavone | Isoflavone | [40] |
| 27  | 6,7-dihydroxy-3’-methoxy-4’, 5’-methylenedioxy isoflavone | Isoflavone | [40] |
| 28  | 6,7-dihydroxy-3’-methoxy-4’, 5’-methylenedioxy isoflavone | Isoflavone | [40] |

Fig. 2. Structures of some common flavonoids in vine tea.
ability to improve glucose and lipid homeostasis and increase the insulin sensitivity. The antidiabetic activity of vine tea and its possible mechanisms are summarized in Table 3 [30,62–70]. α-glucosidase plays a critical role in the degradation of carbohydrates. Chen et al. [30] investigated the α-glucosidase inhibitory activity and hypoglycemic activity of three major components (myricetin, DMY and myricitrin) from Ampelopsis grossedentata as well as six new flavonoid derivatives. The results showed that myricetin an-
alogs exert effective α-glucosidase inhibition in vitro and in strept-
tozotocin (STZ)-induced diabetic mice. In an experiment by Wan et al. [62], the results showed that vine tea regulates glucose and lipid metabolism, increases the insulin sensitivity and improves hepatic lipid accumulation in high-fat diet (HFD)-induced rats. Moreover, the mechanism may be related to the improvement of energy-related metabolism and the decrease of lipid accumulation. Ran et al. [63] reported that Ampelopsis grossedentata is helpful in ameliorating the glucose levels in patients with type 2 diabetes. Wang et al. [45] investigated the α-glucosidase inhibition of two polysaccharides isolated from vine tea. The results exhibited that the two polysaccharides have a stronger α-glucosidase inhibitory potential.

In a study by Le et al. [64], the results indicated that DMY im-
proves insulin resistance in HFD-treated rats. Furthermore, DMY improves insulin resistance, which is related to the activation of the AMP-activated protein kinase (AMPK) signaling pathway to in-
crease glucose uptake. In addition, this activity of DMY is also related to the reduction of the glucose production via the insulin receptor substrates (IRS)/PI3K/Akt pathways. Insulin resistance experiment revealed that DMY can improve the insulin sensitivity in skeletal muscle cells in diabetic patients. Moreover, the auto-
phagy enhancement is good for increasing the insulin sensitivity by DMY. Besides, the protective effect may be related to the activation

**Table 2**

Antioxidant activity of vine tea and its main flavonoids (dihydromyricetin and myricetin).

| In vitro | In vivo | Compound | Observed effects | Refs. |
|----------|---------|----------|------------------|-------|
| DPPH scavenging assay | Vine tea extract | DPPH scavenging activity | [26,33] |
| DPPH’ scavenge assay; ABTS’ + scavenging assay; FRAP assay; H2O2 scavenging activity; O2’ scavenging activity; Measurement of erythrocyte SOD activity and lipid peroxidation level | Piglets | Dihydromyricetin | DPPH’ scavenging activity; H2O2 scavenging activity; | [47] |
| ABTS’ + scavenging assay; DPPH’ scavenging assay | Myricetin | DPPH’ and ABTS’ scavenging activities | [48] |
| Chinese hamster lung fibroblasts (V79-4) cells | Myricetin | DPPH’ scavenging activities | [49] |
| Myricetin | Myricetin | DPPH’ scavenging activity; | [50] |
| | | ROS; †Activities of SOD, CAT and GPx; | |
| | | †PI3K/Akt activation; | |
| | | †MAPK activation; | |
| | | †H2A.X expression; Preventing the DNA damage; | |
| | | †Lipid peroxidation | |
| | | †Nrf2 activation | [51] |

**Fig. 3.** Signaling pathways involved in anti-inflammatory mechanisms of vine tea.
of AMPK-peroxisome proliferator-activated receptor coactivator-1α (PGC-1α)-sirtuin-3 (SIRT3) [65]. Wu et al. [66] reported that DMY has a significant effect on cardiac function and pathological changes in the myocardium in streptozotocin-induced model, and AMPK signaling pathway plays a main role in the protective effect on diabetic cardiomyopathy.

Studies verified the regulatory effect of myricetin on type 2 diabetes by increasing the absorption and utilization of glucose in peripheral tissues. Furthermore, results demonstrated that myricetin has the potential in the alleviation in hyperglycemia and promotion of synthesis of liver glycogen without any serious hepatotoxicity in streptozotocin-induced diabetic rats [67]. In addition, the activity of myricetin is related to its improvement of glycogen metabolism and inhibition of aggregation of islet amyloid polypeptide (IAPP) [68]. Kang et al. [69] found that myricetin can also have a pharmacological effect on glucose metabolism and insulin sensitivity, which is probably related to enhancing the production of β-endorphin and improving the phosphorylation of insulin receptor. A further study by Liu et al. [70] exhibited that myricetin plays a significant effect in regulating insulin resistance by enhancing the post-receptor insulin signaling in experimental rats.

These results indicated that vine tea has a great potential to be an effective drug for diabetes.

### 3.4. Neuroprotective effect

Growing evidence has shown that myricetin has a regulatory effect on the development of neurodegenerative diseases, such as PD and AD. Many researches reported that myricetin can mitigate neurodegenerative diseases by blocking the hyperphosphorylation of tau proteins and interfering with the formation of β-amyloid fibril [71]. The high levels of glutamate can lead to brain disorders. Myricetin has the ability to decrease the content of glutamate from cerebrocortical synaptosomes by blocking voltage-dependent Ca2+ channel [72]. Further evidence showed that myricetin inhibits the production of α-synuclein (αS) fibrils and suppresses the αS to change into oligomers, the vital mechanisms for the development of PD [73]. Myricetin can significantly block the activation of catechol O-methyltransferase (COMT), a key enzyme for the metabolism of levodopa in vitro [74]. Moreover, Moonrungsee et al. [75] demonstrated that myricetin has the ability to reduce tyramine

### Table 3

| In vitro/In vivo | Compound | Observed effects | Refs. |
|----------------|----------|------------------|-------|
| α-glucosidase inhibition assay | Vine tea extract | α-glucosidase inhibitory activity | [30] |
| High-fat diet (HFD)-induced rats | Myricetin, Dihydromyricetin | Regulation of glucose and lipid metabolism; Regulation of tricarboxylic acid (TCA) cycle, amino acid metabolism and purine metabolism | [62] |
| | Patients with type 2 diabetes mellitus | Vine tea | Improvement of hepatic lipid accumulation; Fasting plasma glucose (FPG); Glycated albumin (GA); Retinol binding protein-4 (RBP4); Cystatin C | [63] |
| HepG2 cells | Male Sprague-Dawley (SD) rats | Dihydromyricetin | Improvement of serum glucose and lipid homeostasis; Insulin sensitivity; Regulation of TCA cycle; Glucose uptake; Improvement of the translocation of glucose transporter 1; Phosphorylation of AMP-activated protein kinase (AMPK); Glycogen synthase-3β (GSK-3β) phosphorylation; Phosphorylation of protein kinase B (Akt) Ser474 and insulin receptor substrate-1 (IRS-1) Ser612 | [64] |
| Mouse skeletal muscle | Male 129/SvJ (wild type, WT) and SIRT3−/− 129/SvJ mice | Dihydromyricetin | Improvement of insulin sensitivity; Autophagy; Regulation of Sirt3 functions; Activation of the AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor coactivator-1α (PGC-1α) signaling pathways; Improvement of insulin resistance | [65] |
| Streptozotocin (STZ) induced C57BL/6J mice | Dihydromyricetin | Improvement of cardiac function in STZ-induced diabetic mice; Oxidative stress; Levels of inflammation factors (Interleukin-6, Tumor necrosis factor-α); Improvement of mitochondrial function | [66] |
| Male Wistar rats | Myricetin | Serum glucose levels; Hepatic glycogen synthesis; Absorption and utilization of glucose in peripheral tissues; | [67] |
| E. coli cells | Male Sprague-Dawley rats | Myricetin | Regulation of glucose metabolism | [68] |
| α-glucosidase inhibition assay | Lean (Fa/Fa or Fa/fa) and obese (Fa/Fa) Strains of Zucker rats | Myricetin | Inhibition of aggregation of islet amyloid polypeptide (IAPP); Death of pancreatic β-islet cells | [69] |
| | | | Inhibition of α-glucosidase activity; Improvement of postprandial hyperglycemia; Alleviation of fasting hyperglycemia; Plasma glucose levels; Improvement of insulin resistance; Expression of glucose transporter subtype 4 (GLUT4); The protein and phosphorylation of insulin receptor substrate-1 (IRS-1); Activation of phosphatidylinositol 3-kinase (PI3K) | [70] |
oxidase, which is related to the inactivation of neurotransmitters. In addition, it was found to block the expression of ROS and the per-oxidation of lipid, prevent glutathione (GSHe) depletion, and pro- mote γ-aminobutyric acid (GABA) activity in the neurons [76].

As is known to all, the increase of the level of microRNAs (miRNAs) is related to the aging-related diseases. Devastating neurodegeneration and cognitive dysfunction are the main characteristics of degenerative diseases. DMY adjusts cognitive dysfunction and mitigates neuron necrosis in the brain aging model of rats. Moreover, it can up-regulate sirtuin 1 (SIRT1) and down-regulate p33/p21 [77]. A growing body of evidence suggested that DMY has the ability to attenuate the activity of COMT [78]. Further experiments found that DMY is related to restoring the behavioral damage, protecting DA neurons, and reducing ROS production after dopaminergic neurotoxic compound stimulation [74]. Major depressive disorder (MDD) is a very common disease. A study revealed that DMY-mitigated MDD is attributed to the elevated brain derived neurotrophic factor (BDNF) signaling pathway [79]. Further experiments found that DMY can prevent neuro-degeneration and enhance hypoxia induced cognitive function [80]. The above results indicate that DMY may be an effectively agent for the improvement of neurodegenerative diseases.

3.5. Anticancer activity

A number of researches have reported the prevention of vine tea flavonoids on cancer. Studies confirmed that DMY can promotemitochondria-induced apoptosis in HepG2 cells by down-regulating Akt/Bax and B-cell lymphoma-2 (Bcl-2) associated death promoter (Bad) pathway and inactivating the mammalian target of rapamycin (mTOR) via ERK1/2, AMPK and P38/Akt pathways [81]. In a study, the results showed that DMY might be an effective agent for non-small cell lung cancer (NSCLC) through increasing intracellular peroxide and sustaining the expression of ERK1/2 and JNK1/2 [82]. Another experiment investigated that DMY prevents osteosarcoma, which may be related to suppressing the activation of glycogen synthase-3β (GSK3β) through the activation of AMPKα and p38 signaling pathway [83]. Further experiment revealed that DMY prevents osteosarcoma by inhibiting the expressions of caspase and Bcl-2 [84]. Xu et al. [85] confirmed that DMY might be an effective therapeutic medication for ovarian cancer through inducing cell apoptosis by p33-induced surviving down-regulation. In addition, the ability to treat gastric cancer of DMY may be related to inhibiting proliferation, inducing cell cytotoxicity and promoting apoptosis in human gastric cancer cells [86]. Zhou et al. [87] reported that DMY might be a new therapeutic drug for breast cancer. The results showed that DMY can inhibit cell viability and induce apoptosis in breast cancer cells (MCF-7 and MDA-MB-231 cells) without cytotoxicity in human normal breast epithelial cells (MCF-10A cells) through ROS generation and endoplasmic reticulum (ER) stress pathway. Extensive research indicated that myricetin possesses an anti-proliferative activity against human cancer cell lines, such as hepatic, skin, pancreatic and colon cancer cells, as well as suppresses key enzymes related to the development of cancer. Previous studies showed that myricetin induces the apoptosis of human chronic and acute leukemia cells [88]. Further experiment exhibited that myricetin also inhibits the ability of topoisomerase (topo) I and topo II in K562 cells. Moreover, this activity may be attributed to the hydroxy and carbonyl groups in this compound [89]. Regulating the activity of mitogen-activated protein kinase (MEK), janus kinase 1 (JAK1), Akt and mitogen-activated protein kinase 4 (MKK4) is a prerequisite for anticancer activities of myricetin [90]. Besides, a study reported that myricetin can attenuate STAT3 activity and reduce the activation of STAT3 at tyrosine 705 (Tyr705) and serine 727 (Ser727) [91]. In vitro, myricetin has a significant effect on human laryngeal carcinoma Hep2 cells and prostate cancer PC-3 cells [92]. A mechanism-based study revealed that myricetin attenuates the phosphorylation of Akt and promotes the phosphorylation of p38 MAPK in HepG2 cells [93]. In addition, myricetin was also found to possess anti-proliferative activity against medulloblastoma and lung carcinoma [94].

3.6. Antihypertensive activity

The in vivo and in vitro experiments demonstrated that myricetin possesses an antihypertensive activity, which may be closely related to the decrease of hypertension and oxidative stress. Similarly, studies also revealed that this compound has the capability to modify systolic blood pressure, vascular reactivity and heart rate [95].

3.7. Hepatoprotective activity

A growing body of evidence suggests that vine tea might possess a hepatoprotective activity. The inhibition of apoptosis and adjustment of autophagy-related genes are possibly the main mechanisms for this activity of DMY [96]. Qiu et al. [97] verified that DMY has the ability to improve lipid metabolism and decrease inflammatory cytokines in alcohol-induced liver injury mice. Furthermore, DMY could also increase the level of GSH and decrease the level of malondialdehyde (MDA) in the liver via NF-κB signaling pathway. Studies revealed that DMY has a regulatory ef-fect on nonalcoholic fatty liver disease (NAFLD) by improving lipid metabolism and decreasing oxidative stress. In addition, mecha-nism research indicated that it can effectively increase the level of SIRT3 via AMPK/PGC-1α/estrogen-related receptor-α (ERRα) signaling pathway [98]. Furthermore, previous studies have sug-gested that the hepatoprotective function of DMY may be related to the antioxidant activity [99]. Moreover, growing clinical trials proved the effect of DMY on NAFLD [100].

It was found that myricetin exerts hepatoprotective effects through decreasing the level of serum enzymes and total bilirubin as well as attenuating DNA damage in the liver [101]. Moreover, myricetin can lessen liver uric acid levels and attenuate liver xanthine oxidase activity in potassium oxonate-induced hyperuricemic mice [102].

3.8. Activity against cardiovascular diseases

Inflammation is a critical mechanism in atherosclerosis. DMY possesses the ability to decrease the release of interleukin-1β (IL-1β), inhibit caspase-1 cleavage, and suppress ROS generation during atherosclerosis [103]. Zeng et al. [104] revealed that DMY improves lipid metabolism probably as an effective agent for atherosclerosis. Furthermore, ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) are related to these activities. Several studies revealed that DMY has an anti-atherosclerotic function through many mechanisms. It can ameliorate hyperlipidemia and decrease the levels of inflammatory cytokines as well as inhibit the expression of NF-κB [105].

The cardioprotective effect of DMY is mainly attributed to its antioxidant activity and apoptosis inhibition in vivo and in vitro [106]. One experiment exhibited that DMY has the ability to attenuate the toxicity of adriamycin on the heart [107]. DMY can treat arrhythmia by inhibiting sodium currents and enhancing calcium current [108]. Furthermore, several studies revealed that DMY might be an effective agent to improve myocardial remodel-ing and pulmonary hypertension [109]. Altogether, the above data indicate that DMY may be an effective agent for the improvement
of cardiovascular diseases.

Studies revealed that myricetin exerts protective activity for cardiomyocytes by inhibiting the voltage-dependent Ca\(^{2+}\) channel [110]. Myricetin can reduce the apoptosis of neonatal cardiomyocytes under hypoxic conditions [111]. Tiwari et al. [112] reported that myricetin possesses the ability to reduce heart rate and change vascular reactivity induced by isoproterenol. In addition, myricetin exerts lipid lowering activity and effective function in hyperlipidemia and related cardiovascular diseases [113].

3.9. Other activities

In addition to the above-mentioned activities, vine tea also has bactericidal activity, anti-rheumatoid arthritis and anti-osteoporosis activity, immunomodulatory activity, anti-allergic activity, anti-asthma and other activities. DMY exerts bactericidal activity by disrupting integrity and fluidity of membrane and interacting with intracellular DNA in Staphylococcus aureus [114]. Several studies revealed that DMY may be beneficial to the prevention of osteoelast-related diseases through multiple pathways [115].

Myricetin can ameliorate physiological disorders through the improvement of the release of melatonin [116]. Moreover, several studies exhibited that myricetin has an effectively antiphotaging function by inhibiting free radicals in the skin [117]. Myricetin exerts immunosuppressive effects by promoting antibody production or suppressing the activity of white blood cells (WBCs) [118]. Moreover, results indicated that myricetin possesses an anti-allergic activity [119]. Furthermore, Hagenacker et al. [120] reported that myricetin exerts an effective analgesic action in a neuropathic pain model. Besides, several researches showed that myricetin possesses antibacterial and antiviral activities through different organisms [121,122]. In addition, previous studies revealed that myricetin ameliorates the development of cataract [123].

4. Conclusions and future perspectives

*Ampelopsis grossedentata* has been used as healthy tea, beverage and herbal medicine for hundreds of years, and flavonoids are identified to be the main bioactive ingredient in it. Apart from DMY and myricetin, the most abundant flavonoids in vine tea, it also contains quercetin, kaempferol, hesperidin, apigenin, rutin and other common flavonoids. It is worth noting that quercetin, kaempferol and rutin also exhibit a wide range of significant bioactivities including anti-oxidant, anti-inflammatory, anti-tumor, anti-diabetic, and neuroprotective effects [124]. Therefore, vine tea, a functional nutraceutical, possesses a variety of biological activities and highly health promoting properties.

Although researchers have investigated the various bioactivities of vine tea, so far, the specific mechanism of vine tea remains unclear, which may be attributed to the anti-oxidation, anti-inflammation, anti-apoptosis and other pathways. As we all know, most common flavonoids usually have low oral bioavailability [125]. However, vine tea possesses various pharmacological activities. Therefore, extensive knowledge of the absorption and metabolic mechanisms as well as the bioavailability of vine tea is essential if its pharmacological activities are to be understood in the near future. On the one hand, the pharmacological effects of natural products depend on integrating ingredients rather than single or two main ingredients. Furthermore, some low content compounds are proved to exert significant bioactivities. Moreover, some low content ingredients have been developed into clinical drugs or lead compounds, such as paclitaxel and vincristine [126]. On the other hand, only compounds absorbed by the body can exert an effect; however, metabolites formed during liver metabolism and micro-bial catabolism of the parent compounds may be responsible for the effects. Consequently, it is important to comprehensively investigate bioactive compounds in vine tea and serum pharmacology and serum pharmacochemistry characteristics of vine tea in the near future.

Anyway, regarding its pharmacological activities, vine tea is an excellent herbal medicine, part of the Chinese tea culture. It is a promising herbal medicine for preventing initiation and progression of several diseases. Most reports to date have focused on bioactivity testing, so comprehensively serum pharmacology and serum pharmacochemistry as well as exhaustive mechanistic and toxicological studies or preresearch studies on vine tea are necessary for the development of commercial drugs in the future.

Declaration of competing interest

The authors declare that there are no conflicts of interest.

References

[1] C.S. Yang, G. Chen, Q. Wu, Recent scientific studies of a traditional Chinese medicine, tea, on prevention of chronic diseases, J. Tradit. Complem. Med. 4 (2014) 17–23.
[2] W. Xiao, Y. Peng, L. Xu, et al., Preliminary exploration of the diversity of the Chinese tea culture, Mod. Chin. Med. 13 (2011) 52, 53, 59.
[3] Z.D. He, Y. Peng, P.G. Xiao, Kudingcha Research and Development, Science Press, Beijing, 2010, pp. 1–25.
[4] W. Xiao, Y. Peng, L. Xu, et al., The origin of the tea culture and the “chew-drink” concept, Mod. Chin. Med. 13 (2011) 45–46.
[5] L.Y. Ye, H.J. Wang, S.E. Duncan, et al., Antioxidant activities of vine tea (*Ampelopsis grossedentata*) extract and its major component dihydromyricetin in soybean oil and cooked ground beef, Food Chem. 172 (2015) 416–422.
[6] J.H. Gao, B.G. Liu, Z.X. Niog, et al., Characterization and antioxidant activity of flavonoid-rich extracts from leaves of *Ampelopsis grossedentata*, J. Food Biochem. 336 (2009) 808–820.
[7] M. Fu, X.Y. Li, D.Y. Wang, et al., Flavonoid constituents of leaves of *Ampelopsis grossedentata* (Hand-Mazz) W.T. Wang, Chin. Pharmaceut. J. 50 (2015) 574–578.
[8] C. Wang, W. Xiong, S. Reddy Perumalla, et al., Solid-state characterization of optically pure (-) dihydromyricetin extracted from *Ampelopsis grossedentata* leaves, Int. J. Pharm. 511 (2016) 245–252.
[9] V. Georgiev, A. Ananga, V. Tsolova, Recent advances and uses of grape flavonoids as nutraceuticals, Nutrients 6 (2014) 391–415.
[10] S. Chen, X. Zhao, J. Wan, et al., Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: a randomized controlled trial, Pharm. Res. (N. Y.) 99 (2015) 74–81.
[11] Y. Wu, B. Wu, J. Wan, et al., Rattan tea extracts improve insulin resistance in type 2 diabetes rats, J. Third Mil. Med. Univ. 37 (2015) 454–458.
[12] B.P. Jiang, L. Le, H.M. Pan, et al., Dihydromyricetin ameliorates the oxidative stress response induced by methylglyoxal via the AMPK/GLUT4 signaling pathway in PC12 cells, Brain Res. Bull. 109 (2014) 117–126.
[13] L. Ying, P. Xu, S.R. Huang, et al., Antioxidant activity of bioactive compounds extracted from *Ampelopsis grossedentata* leaves by optimized supercritical carbon dioxide, J. Med. Plants Res. 5 (2011) 4373–4381.
[14] Y. Ye, X.H. Ou, Q.J. Huang, et al., Antithrombotic effect of total flavonoids and monomeric compounds from *Ampelopsis grossedentata*, Tradit. Chin. Drug Res. Clin. Pharmacol. 24 (2013) 33–38.
[15] J. Liu, Y. Shu, Q. Zhang, et al., Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells, Oncol. Lett. 8 (2014) 1645–1651.
[16] Y. Zhou, X.Y. Liang, H. Chang, et al., Ampelopsis-induced autophagy protects breast cancer cells from apoptosis through Akt-mTOR pathway via endoplasmic reticulum stress, Canc. Sci. 105 (2014) 1279–1287.
[17] X.L. Hou, Q. Tong, W.Q. Wang, et al., Suppression of inflammatory responses by dihydromyricetin, a flavonoid from *Ampelopsis grossedentata*, via inhibiting the activation of NF-κappa B and MAPK signaling pathways, J. Nat. Prod. 78 (2015) 1689–1696.
[18] C.H. Zeng, K. Yang, M.C. Xu, et al., Antibacterial mechanisms of total flavonoids from *Ampelopsis grossedentata* on Staphylococcus aureus, Chin. J. Exp. Tradit. Med. Formulae 19 (2013) 249–252.
[19] Y.C. Zhou, Y.X. Hu, X.B. Zang, et al., Toxicological assessment on *Ampelopsis grossedentata* and its immune regulation study, Pract. Prev. Med. 8 (2001) 412–414.
[20] M. Naveed, J. Bibi, A.A. Kamboh, et al., Pharmacological values and therapeutically properties of black tea (*Camellia sinensis*): a comprehensive overview, Biomed. Pharmacother. 100 (2018) 521–531.
the anti-inflammatory effects of Ampelopsis grossedentata on dextran sodium sulfate-induced colitis, World J. Gastroenterol. 24 (2018) 1398–1409.

[34] X. Li, H. Qiu, T.Q. Wang, et al., Suppression of inflammatory responses by dihydromycetin, a flavonoid from Ampelopsis grossedentata, via inhibiting the activation of NF-κB and MAPK signaling pathways, J. Nat. Prod. 78 (2015) 1689–1696.

[35] G. Guo, H. Zhang, X. Li, et al., Ampelopsin attenuates lipopolysaccharide-induced inflammatory response through the inhibition of the NF-κB and JAK2/STAT3 signaling pathways in microglia, Int. Immunopharmac. 44 (2017) 119–126.

[36] J. Wu, F.T. Zhao, K.J. Fan, et al., Dihydromycetin inhibits inflammation of fibroblast-like synoviocytes through regulation of nuclear factor-κB signaling in rats with collagen-induced arthritis, J. Pharmacol. Exp. Therapeut. 368 (2019) 218–228.

[37] D. Grosser, H. Chen, A.B. Lagha, et al., Dual action of myricetin on Porphyrion goniosin and the inflammatory response of host cells: a promising therapeutic molecule for periodontal diseases, PloS One 10 (2015), e0131758.

[38] G. Gutiérrez-Venegas, O.A. Luna, Arreguín-Canó, et al., Myricetin blocks lipotoxic acid-induced COX-2 expression in human gingival fibroblasts, Cell. Mol. Biol. Lett. 19 (2014) 126–139.

[39] H.H. Kim, D.H. Kim, M.H. Kim, et al., Flavonoid constituents in the leaves of Myrica rubra sieb, et zucc. with anti-inflammatory activity, Arch Pharm. Res. (Seoul) 36 (2013) 1533–1540.

[40] K.M. Lee, N.J. Kang, J.H. Han, et al., Myricetin down-regulates phosphor ester-induced cycloxygense-2 expression in mouse epidermal cells by blocking expression of nuclear factor kappa B, J. Agric. Food Chem. 55 (2007) 9678–9684.

[41] Y.S. Lee, E.M. Choi, Myricetin inhibits L-16-induced inflammatory mediators in human synovial sarcoma cells, Int. Immunopharm. 10 (2010) 812–814.

[42] R.C. Schwane, R. Marcon, F.C. Moetti, et al., Oral administration of the flavonoid myricetin prevents dextran sulfate sodium-induced experimental colitis in mice through modulation of PI3K/Akt signaling pathway, Mol. Nutr. Food Res. 57 (2013) 1938–1949.

[43] W.T. Wan, B.P. Jiang, L. Sun, et al., Metabolomics reveals that vine tea (Ampelopsis grossedentata) prevents high-fat-diet-induced metabolism disorder by improving glucose homeostasis in rats, PloS One 12 (2017), e0182830.

[44] L. Ran, X.L. Wang, H.D. Lang, et al., Ampelopsis grossedentata supplementation effectively ameliorates the glycemic control in patients with type 2 diabetes mellitus, Arch. Med. Sci. 11 (2015) 1897–1902.

[45] L. Le, B.P. Jiang, W.T. Wan, et al., Metabolomics reveals the protective of dihydromycetin on glucose homeostasis by enhancing insulin sensitivity, Sci. Rep. 6 (2016), 36184.

[46] L.Y. Shi, T. Zhang, Y. Zhou, et al., Dihydromycetin improves skeletal muscle insulin sensitivity by inducing autophagy via the AMPK-PGC-1α-Sirt3 signaling pathway, Endocrine 50 (2015) 378–389.

[47] B. Wu, J. Lin, J. Luo, et al., Dihydromycetin protects against diabetic cardiomyopathy in streptozotocin-induced diabetic mice, Bio Med Res. Int. (2017), 3764370.

[48] K.C. Ong, H.E. Kho, Effects of myricetin on glycemia and glycogen metabolism in diabetic rats, Life Sci. 67 (2000) 1695–1705.

[49] C. Zelus, A. Fox, A. Calciano, et al., Myricetin inhibits islet amyloid polypeptide (IAPP) aggregation and rescues living mammalian cells from IAPP toxicity, Open Biochem. J. 6 (2012) 66–70.

[50] S.J. Kang, J.H.Y. Park, H.N. Choi, et al., α-glucosidase inhibitory activities of myricetin in animal models of diabetes mellitus, Food Sci. Biotechnol. 24 (2015) 1897–1900.

[51] J.M. Liu, T.F. Zheng, S.S. Liou, et al., Improvement of insulin sensitivity in obese Zucker rats by myricetin extracted from Abiesboschus moschatus, Planta Med. 73 (2007) 1054–1064.

[52] Y. Choi, T.D. Kim, S.R. Paik, et al., Molecular simulations for anti-amyloidogenic effect of flavonoid myricetin exerted against Alzheimer’s P-amyloid fibril formation, Bull. Kor. Chem. Soc. 29 (2008) 1505–1509.

[53] Y. Chang, C.Y. Chang, J.H.Y. Park, et al., Myricetin inhibits the release of glutamate in rat cerebocortical nerve terminals, J. Med. Food 18 (2015) 516–523.

[54] J.M. Jurisana, T. Hogen, J. Levin, et al., Inhibition and disaggregation of socalled oligomers by natural polyphenolic compounds, FEBS Lett. 585 (2011) 1113–1120.

[55] X. Zhu, Y.H. Jia, Inhibition of catechol-o-methyltransferase (COMT) by myricetin, dihydromycetin and myricitrin, Pharmazie 69 (2014) 183–186.

[56] N. Moonrungsee, T. Shimamura, T. Kashivagi, et al., An automated sequential injection spectrophotometric method for evaluation of tyramine oxidation inhibitory activity of some flavonoids, Talanta 122 (2014) 257–263.

[57] Y.H. Zhang, Z.G. Feng, M.H. Rowlands, et al., Flavonoid myricetin modulates GABAA receptor activity through activation of Ca2+ channels and CaMK-II pathway, Evid. Based Compl. Alt. Med. 2012 (2012), 758907.

[58] Y.Y. Jin, P. Singh, H.J. Chung, et al., Blood ammonia as a possible etiological factor for Alzheimer’s dementia, J. Alzheimers Dis. 7 (2006) 12–18.

[59] Z.X. Ren, Y.F. Zhao, T. Cao, et al., Dihydromycetin protects neurons in a MPP+-induced model of Parkinson’s disease by suppressing glycogen synthase kinase-3 β activity, Acta Pharmacol. Sin. 37 (2016) 1315–1324.

[60] Z. Ren, P. Yan, L. Zhu, et al., Dihydromycetin exerts a rapid antidepressant-
like effect in association with enhancement of BDNF expression and inhibition of neuroinflammation, Psychopharmacol. (Berl) 235 (2018) 233–244.

[101] S.F. Mo, F. Zhou, Y.Z. Lv, et al., Hypouricemic action of selected flavonoids in mice: structure-activity relationships, Biol. Pharm. Bull. 30 (2007) 1551–1556.

[102] Q. Hu, T. Zhang, L. Yi, et al., Dihydromyricetin inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells, BioFactors 44 (2018) 123–136.

[103] Y. Zeng, Y. Peng, K. Tang, et al., Dihydromyricetin ameliorates foam cell formation via LXRA-ABCA1/ABCG1-dependent cholesterol efflux in macrophages, Biomed. Pharmacother. 101 (2018) 543–552.

[104] T.T. Liu, Y. Zeng, K. Tang, et al., Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice, Atherosclerosis 262 (2017) 39–50.

[105] S. Liu, Q. Ai, K. Feng, et al., The cardioprotective effect of dihydromyricetin prevents ischemia-reperfusion-induced apoptosis in vivo and in vitro via the PI3K/Akt and HIF-1α signaling pathways, Apoptosis 21 (2016) 1366–1385.

[106] H. Zou, P.H. Luo, Y.Y. Fu, et al., Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin, Oncotarget 6 (2015) 3254–3267.

[107] Y. Wang, L. Fu, L. Wang, et al., Electrophysiological study on the antiarrhythmic mechanism of amelopin in rats, Chin. J. Cardiovas. Dis. 42 (2014) 675–679.

[108] Q. Li, J. Wang, X. Zhi, et al., Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats, Biomed. Pharmacother. 96 (2017) 825–833.

[109] C.L. Gan, F.Z. Liu, S.X. Jiang, et al., Effects of five flavonoids on [Ca2+]i in cardiomyocytes of rats, Chin. J. Epidemiol. 26 (2007) 624–628.

[110] T.M. Scabelli, S. Mariotto, S. Abdel-Azeim, et al., Targeting STAT1 by myricetin and delphinidin provides sufficient protection of the heart from ischemia/reperfusion-induced injury, FEBs Lett. 583 (2009) 531–541.

[111] R. Tiwari, M. Mohan, S. Kasture, et al., Cardioprotective potential of myricetin in isoproterenol-induced myocardial infarction in Wistar rats, Physiother Res. 23 (2009) 1361–1366.

[112] G. Bhatia, A.K. Khanna, R. Sonkar, et al., Lipoic acid and antioxidant activity of flavonoids in triton treated hyperlipidemic rats, Med. Chem. Res. 20 (2011) 1622–1626.

[113] Y. Wu, J. Bai, K. Zhong, et al., A dual antibacterial mechanism involved in membrane disruption and DNA binding of 2R,3R-dihydromyricetin from pine needles of Cedrus deodara against Staphylococcus aureus, Food Chem. 218 (2017) 463–470.

[114] L. Zhao, C. Cai, J. Wang, et al., Dihydromyricetin protects against bone loss in ovariectomized mice by suppressing osteoclast activity, Front. Pharmacol. 8 (2017), 528.

[115] J.C. Shin, H.Y. Jung, A. Harihaski, et al., The flavonoid myricetin reduces nocturnal melatonin levels in the blood through the inhibition of serotonin N-acetyltransferase, Biochem. Biophys. Res. Co. 440 (2013) 312–316.

[116] T. Kumanoto, M. Fuji, D.X. Hou, Akt is a direct target for myricetin to inhibit cell transformation, Mol. Cell. Biochem. 312 (2009) 33–41.

[117] B.Y. Kang, S.H. Kim, D. Cho, et al., Inhibition of interleukin-12 production in mouse macrophages via decreased nuclear factor-kappa B DNA binding activity by myricetin, a naturally occurring flavonoid, Arch Pharm. Res. (Seoul) 28 (2005) 274–279.

[118] H.H. Park, S. Lee, H.Y. Son, et al., Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells, Arch Pharm. Res. (Seoul) 31 (2008) 1303–1309.

[119] T. Hagenack, I. Hildebrand, A. Wissmann, et al., Anti-allodynic effect of the flavonoid myricetin in a rat model of neuropathic pain: involvement of p38 and protein kinase C-mediated modulation of Ca2+ channels, Eur. J. Pain 14 (2010) 992–998.

[120] L. D’Souza, S. Wahdulla, P. Devi, Antibacterial phenolics from the mangrove Lumnitzera racemosa, Indian J. Mar. Sci. 39 (2010) 294–298.

[121] H.X. Xu, S.F. Lee, Activity of plant flavonoids against antibiotic-resistant bacteria, Phytother Res. 15 (2001) 39–43.

[122] R. Chen, M. Hollborn, A. Grosche, et al., Effects of the vegetable polyphenols epigallocatechin-3-gallate, luteolin, apigenin, myricetin, quercetin, and cyanidin in primary cultures of human retinal pigment epithelial cells, Mol. Vis. 20 (2014) 242–258.

[123] B. Russo, F. Picconi, I. Malandrucco, et al., Flavonoids and insulin-resistance: from molecular evidences to clinical trials, Int. J. Mol. Sci. 20 (2019) 2061.

[124] C. Manach, A. Scalbert, C. Morand, et al., Polyphenols: food sources and bioavailability, Am. J. Clin. Nutr. 79 (2004) 727–747.

[125] N.H. Ouberlies, D.J. Kroll, Camptothecin and taxol: historic achievements in cancer chemotherapy, Pharmacol. Res. 755 (2013) 72–82.